Clinical significance of sFlt-1/PlGF in the diagnosis and prediction of preeclampsia

1. Say L., Chou D., Gemmill A., Tuncalp O., Moller A.-B., Daniels J. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob. Health. 2014; 2: e323-33. https://dx.doi.org/10.1016/S2214-109X(14)70227-X.
2. Шалина Р.И., Михалева Л.М., Симухина М.А., Коноплянников А.Г., Штабницкий А.М. Особенности течения тяжелых форм преэклампсии в современных условиях. Вопросы гинекологии, акушерства и перинатологии. 2017; 16(6): 16-23. [Shalina R.I., Mikhaleva L.M., Simukhina M.A., Konoplyannikov A.G., Shtabnitsky A.M. Features of the course of severe forms of preeclampsia in modern conditions. Questions of gynecology, obstetrics and perinatology. 2017; 16(6): 16-23. (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2017-6-16-23.
3. Sibai B.M., Stella C.L. Diagnosis and management of atypical preeclampsia-eclampsia. Am. J. Obstet. Gynecol. 2009; 200(5): 481. e1-7. https://dx.doi.org/10.1016/j.ajog.2008.07.048.
4. Сидорова И.С., Никитина Н.А., Унанян А.Л. Преэклампсия и снижение материнской смертности в России. Акушерство и гинекология. 2018; 1: 107-12. [Sidorova I.S., Nikitina N.A., Unanyan A.L. Preeclampsia and reduction of maternal mortality in Russia. Obstetrics and gynecology. 2018; 1: 107-11. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.1.107-112.
5. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111(5): 649-58. https://dx.doi.org/10.1172/JCI17189.
6. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006; 355(10): 992-1005. https://dx.doi.org/10.1056/NEJMoa055352.
7. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 2004; 95(9): 884-91. https://dx.doi.org/10.1161/01.RES.0000147365.86159.f5.
8. Palm M., Basu S., Larsson A., Wernroth L., Kerud H., Axelsson O. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet. Gynecol. Scand. 2011; 90(11): 1244-51. https://dx.doi.org/10.1111/j.1600-0412.2011.01186.x.
9. Иванец Т.Ю., Алексеева М.Л., Логинова Н.С., Колодько В.Г., Насонова Д.М., Хасьянова З.Ш. Плацентарный фактор роста и fms-подобная тирозинкиназа-1 как маркеры преэклампсии в динамике беременности. Клиническая лабораторная диагностика. 2013; 8: 14-7. [Ivanets T.Yu., Alekseeva M.L., Loginova N.S., Kolodko V.G., Nasonova D.M., Khasyanova Z.Sh. Placental growth factor and fms-like tyrosine kinase-1 as markers of preeclampsia in pregnancy dynamics. Clinical laboratory diagnostics. 2013; 8: 14-7. (in Russian)].
10. Verlohren S., Galindo A., Schlembach D., Zeisler H., Herraiz I., Moertl M.G. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010; 202(2): 161. e1. 161. e11. https://dx.doi.org/10.1016/j.ajog.2009.09.016.
11. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Moertl M., Zeisler H. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 2012; 206(1): 58. e1-8. https://dx.doi.org/10.1016/j.ajog.2011.07.037.
12. Rana S., Powe C.E., Salahuddin S., Verlohren S., Perschel F.H., Levine R.J. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012; 125(7): 911-9. https://dx.doi.org/10.1161/CIRCULATIONAHA.111.054361.
13. Gomez-Arriaga P., Herraiz I., Lopez-Jimenez E.A., Escribano D., Denk B., Galindo A. Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset preeclampsia. Ultrasound Obstet. Gynecol. 2014; 43(5): 525-32. https://dx.doi.org/10.1002/uog.13224.
14. Курцер М.А., Шаманова М.Б., Синицына О.В., Николаев А.А., Николаева Е.В., Дедловская А.И., Самсонова М.А. Использование тест-системы Elecsys PlGF и sFLT-1 с целью прогнозирования перинатальных исходов у пациенток с тяжелой преэклампсией. Акушерство и гинекология. 2019; 10: 96-104. [Kurtser M.A., Shamanova M.B., Sinitsina O.V., Nikolaev A.A., Nikolaeva E.V., Dedlovskaya A.I., Samsonova M.A. The use of Elecsys PlGF and sFlt-1 test systems to predict perinatal outcomes in patients with severe preeclampsia. Obstetrics and Gynecology. 2019; 10: 96-104. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.10.162-170.
15. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase– specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014; 63(2): 346-52. https://dx.doi.org/10.1161/HYPERTENSIONAHA.113.01787.
16. Simón E., Permuy C., Sacristán L., Zamoro-Lorenci M.J., Villalaín C., Galindo A., Herraiz I. sFlt-1/PlGF ratio for the prediction of delivery within 48 hours and adverse outcomes in expectantly managed early-onset preeclampsia. Pregnancy Hypertens. 2020; 22: 17-23. https://dx.doi.org/10.1016/j.preghy.2020.07.007.
17. Tasta O., Parant O., Hamdi S.M., Allouche M., Vayssiere C., Guerby P. Evaluation of the prognostic value of the sFlt-1/PlGF ratio in early-onset preeclampsia. Am. J. Perinatol. 2020 May 23. https://dx.doi.org/10.1055/s-0040-1709696.
18. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennström M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016; 374(1): 13-22. https://dx.doi.org/10.1056/NEJMoa1414838.
19. Bian X., Biswas A., Huang X., Lee K., Kwok-To Li T., Masuyama H. et al. Short-term prediction of adverse outcomes using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) ratio in Asian women with suspected preeclampsia. Hypertension. 2019; 74(1): 164-72. https://dx.doi.org/10.1161/HYPERTENSIONAHA.119.12760.
20. Sabrià E., Lequerica-Fernández P., Ganuza P.L., Ángeles E.E., Escudero A.I., Martínez-Morillo E., Alvárez F.V. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible? Chem. Lab. Med. 2018; 56(2): 303-11. https://dx.doi.org/10.1515/cclm-2017-0443.
21. Курцер М.А., Шаманова М.Б., Синицина О.В., Николаева А.А., Дедловская А.И., Самсонова М.А. Клиническое обоснование определения соотношения sFlt-1/PlGF с целью раннего выявления и оценки степени тяжести преэклампсии. Акушерство и гинекология. 2018; 11: 114-20. [Kurtser M.A., Shamanova M.B., Sinitsina O.V., Nikolaeva A.A., Dedlovskaya A.I., Samsonova M.A. Clinical rationale for determinig the ratio sFlt–1/PIGF for the early detection and evaluation of the severity of preeclampsia. Obstetrics and Gynecology. 2018; 11: 114-20. (in Russian)]. doi.org/10.18565/aig.2018.11.114-120.
22. Ходжаева З.Х., Холин А.М., Шувалова М.П., Иванец Т.Ю., Демура С.А., Галичкина И.В. Российская модель оценки эффективности теста на преэклампсию sFlt-1/PlGF. Акушерство и гинекология. 2019; 2: 52-8. [Khodzhaeva Z.S., Kholin A.M., Shuvalova M.P., Ivanets T.Yu., Demura S.A., Galichkina I.V. A Russian model for evaluating the efficiency of the sFlt-1/PlGF test for preeclampsia. Obstetrics and Gynecology. 2019; 2: 52-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.2.52-58
23. Беженарь В.Ф., Смирнов А.В., Тимирбулатов Р.Р., Габелова К.А., Шапкайц В.А., Нестеров И.М. Почечная дисфункция при преэклампсии: прогнозирование и дифференциальный диагноз. Часть 1. Доктор.Ру. 2020; 19(6): 23-9. https://dx.doi.org/10.31550/1727-2378-2020-19-6-23-29. [Bezhenar V.F., Smirnov A.V., Timirbulatov R.R., Gabelova K.A., Shapkaits V.A., Nesterov I.M. Renal dysfunction in preeclampsia: prognosis and differential diagnosis. Part 1. DoctorRu. Gynecology. 2020; 19(6): 23-9. (in Russian)]. https://dx.doi.org/10.31550/1727-2378-2020-19-6-23-29.
24. Никольская И.Г., Прокопенко Е.И., Ватазин А.В., Будыкина Т.С. Ангиогенные и антиангиогенные факторы у беременных с хронической болезнью почек: роль коэффициента sFlt-1/PlGF в прогнозировании и диагностике преэклампсии. Нефрология и диализ. 2016; 18(4): 440-51. [Nikolskaya I.G., Prokopenko E.I., Vatazin A.V., Budykina T.S. Angiogenic and antiangiogenic factors in pregnant women with chronic kidney disease: the role of the sFlt-1/PlGF coefficient in the prognosis and diagnosis of preeclampsia. Nephrology and dialysis. 2016; 18(4): 440-51. (in Russian)].
25. Agrawal S., Cerdeira A.S., Redman C., Vatish M. Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosinekinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study. Hypertension. 2018; 71(2): 306-16. https://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10182.
26. Приказ Министерства здравоохранения Московской области № 1072 от 23.07.2018 «Об организации работы по раннему скринингу преэклампсии у беременных в Московской области». [Order of the Ministry of Health of the Moscow Region No. 1072 of 23.07.2018 "On the organization of work on early screening of preeclampsia in pregnant women in the Moscow region". (in Russian)].
27. Stepan H., Hund M., Dilba P., Sillman J., Schlembach D. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Clin. Chem. Lab. Med. 2019; 57(9): 1339-48. https://dx.doi.org/10.1515/cclm-2018-1228.
28. Резолюция Совета экспертов «Нормативный регламент и вопросы организации скрининга и прогнозирования преэклампсии в РФ». Акушерство и гинекология. 2021; 5: 219-21. [Resolution of the Council of Experts "Regulatory guidelines and issues relating to the organization of screening and prediction of preeclampsia in the Russian Federation". Obstetrics and Gynecology. 2021; 5: 219-21. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.5.219-221.

Received 12.07.2021

Accepted 14.07.2021